Charles River Laboratories International Inc. (CRL) Financial Statements (2026 and earlier)

Company Profile

Business Address 251 BALLARDVALE ST
WILMINGTON, MA 01887
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)
Annual | Quarterly

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments195277234242229239
Cash and cash equivalent195277234241228238
Short-term investments    111
Restricted cash and investments1066430
Receivables721780752650618514
Inventory, net of allowances, customer advances and progress billings279380256199186161
Inventory279380256199186161
Prepaid expense1038889949753
Other current assets      0
Other undisclosed current assets9678101856854
Total current assets:1,4031,6091,4391,2741,2011,021
Noncurrent Assets
Operating lease, right-of-use asset412394392293178140
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization     1,1241,044
Long-term investments and receivables218244312   
Long-term investments218244312   
Intangible asset, including goodwill, after accumulated amortization3,5703,9593,8053,7732,5972,230
Goodwill2,8473,0952,8502,7121,8091,541
Intangible asset, excluding goodwill, after accumulated amortization7238649551,061788689
Deferred income tax assets424041403845
Other noncurrent assets278309148353353213
Other undisclosed noncurrent assets1,6041,6401,4661,291  
Total noncurrent assets:6,1256,5866,1645,7504,2903,671
TOTAL ASSETS:7,5288,1957,6037,0245,4914,693
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities372397426673479409
Employee-related liabilities✕✕✕✕246207159
Accounts payable140169206198122111
Accrued liabilities232228220229150139
Deferred revenue248242264220208172
Debt36435039
Business combination, contingent consideration, liability  13   
Other liabilities19420320513810291
Other undisclosed current liabilities176208180   
Total current liabilities:9941,0551,0921,033840710
Noncurrent Liabilities
Long-term debt and lease obligation, including:2,2402,6472,7082,6641,9301,850
Finance lease, liability262628252628
Other undisclosed long-term debt and lease obligation2,2152,6212,6792,3861,7481,706
Liabilities, other than long-term debt786834780583495429
Deferred income tax liabilities107191216240217167
Liability, pension and other postretirement and postemployment benefits    757379
Other liabilities195223175243205183
Operating lease, liability484419390253156116
Business combination, contingent consideration, liability    25  
Other undisclosed noncurrent liabilities    1538337
Total noncurrent liabilities:3,0263,4813,4883,3992,5072,316
Total liabilities:4,0204,5364,5794,4323,3473,026
Temporary equity, including noncontrolling interest415742532529
Equity
Equity, attributable to parent3,4623,5972,9762,5352,1151,635
Common stock111100
Additional paid in capital1,9661,9061,8051,7181,6281,532
Accumulated other comprehensive loss(317)(196)(262)(165)(139)(178)
Retained earnings1,8121,8871,433981625280
Equity, attributable to noncontrolling interest555443
Total equity:3,4673,6022,9812,5392,1181,638
TOTAL LIABILITIES AND EQUITY:7,5288,1957,6037,0245,4914,693

Income Statement (P&L) ($ in millions)
Annual | Quarterly

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues4,0504,1293,9763,5402,9242,621
Cost of revenue
(Cost of Product and Service Sold)		(47)     
Gross profit:4,0034,1293,9763,5402,9242,621
Operating expenses(1,104)(885)(812)(745)(641)(607)
Other undisclosed operating loss(2,671)(2,627)(2,513)(2,206)(1,850)(1,663)
Operating income:227617651590433351
Nonoperating income (expense)(8)10131(35)10114
Investment income, nonoperating951112
Other nonoperating income (expense)(17)9631(36)10012
Interest and debt expense(126)(141)(59)(74)(86)(61)
Income (loss) from continuing operations before equity method investments, income taxes:93577623481447304
Other undisclosed income from continuing operations before income taxes  4    
Income (loss) from continuing operations before income taxes:93581623481447304
Income tax expense(68)(101)(130)(82)(82)(50)
Income (loss) from continuing operations:25480493399365254
Income before gain (loss) on sale of properties:✕✕✕✕399365254
Net income (loss):25480493399365254
Net loss attributable to noncontrolling interest(3)(6)(6)(8)(1)(2)
Net income (loss) attributable to parent:22475486391364252
Preferred stock dividends and other adjustments  3(4)   
Other undisclosed net loss available to common stockholders, basic (12)     
Net income (loss) available to common stockholders, diluted:10478483391364252

Comprehensive Income ($ in millions)
Annual | Quarterly

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):25480493399365254
Other comprehensive income (loss)7(9)24(15)(5)
Other undisclosed comprehensive income (loss)(131)73(103)(29)56(0)
Comprehensive income (loss):(98)545392374406249
Comprehensive loss, net of tax, attributable to noncontrolling interest(0)(5)(3)(9)(2)(2)
Comprehensive income (loss), net of tax, attributable to parent:(99)540389365403247

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: